Table 3 Key themes identified from patient telephone interviews and HCP advisory board meetings
Trial stage | Patients (N = 10) | GPs (n = 9) | PMs (n = 7) |
|---|---|---|---|
Pre-trial experience | Positive | Positive | Positive |
• Personal health benefit • Supporting science • Access to new treatment • Altruism | • Financial benefits • Trial research nurse team • Patient benefit • Influence of other participating sites • Access to hard-to-reach patients • Sponsor communication/support • Inclusion and exclusion criteria | • Patient benefit • Practice financial benefit • Novel study design • Access hard-to-reach patients • Achieve QOF targets • Elicit large data source | |
| Â | Negative | Negative | |
|  | • Room availability • Recruitment | • Room availability • SLS training • Recruitment • Data collection process | |
Experience during the trial | Positive | Positive | Positive |
• Trial research nurse team • Study assessments • Study location • Free prescriptions | • Expectations met • Negative pre-conceptions dispelled • Patient knowledge of condition • Better quality of care • Study organization • Trial research nurse team • Minimal burden on workload | • Expectations met • Knowledge from practice nurses • Patient health improvement • Study organization • Minimal impact on practice • Reduced practice workload • Sponsor support • Trial research nurse team | |
Negative | Negative | Negative | |
• Not receiving study treatment • No study results • Non-participating pharmacies | • Prescriptions • eCRF system • Training • Trial staff turnover • Recruitment • Non-participating pharmacies | • Financial burden (e.g. patient reimbursement) • Invoice/prescription system • Trial staff turnover • Transfer and data storage • Room availability • Reporting hospitalizations | |
Post-trial experience | Positive | Positive | Positive |
• Improved knowledge of condition • Involved in a research study • Improved inhaler adherence • Improved symptoms and health | • Treatment effectiveness • Patient treatment satisfaction • Willingness to prescribe study drug • Professional development • Confidence in research | • High degree of satisfaction • Expectations surpassed • Financial benefit invested in the practice | |
Negative | Negative | Negative | |
• Did not receive COPD PLS | • Unaware of COPD results and COPD PLS • No incentive to share results | • Unaware of COPD results and COPD PLS • Current PLS of low value to patients | |
Future trial experience | Positive | Positive | Positive |
• High likelihood of participating in research • Involvement in design of studies | • High likelihood of participating in research • Confidence in actively seeking research • Involvement in design of studies | • High likelihood of participating in research • Increased confidence to participate • Involvement in design of studies • Role similar with that in SLS | |
Negative | Â | Negative | |
• Unlikely to actively seek research |  | • Impact of GDPR implementation • Unlikely to actively seek research |